

# A Meta-Analysis of Prosthodontic Complication Rates of Implant-Supported Fixed Dental Prostheses in Edentulous Patients After an Observation Period of at Least 5 Years

Theodora Bozini, DDS<sup>1</sup>/Haralampos Petridis, DDS, MSc, PhD<sup>2</sup>/  
Konstantinos Tzanas, BS, MSc<sup>3</sup>/Pavlos Garefis, DDS, PhD<sup>4</sup>

**Purpose:** To systematically review clinical studies on prosthodontic complication rates of implant fixed dental prostheses in edentulous patients after an observation period of at least 5 years.

**Materials and Methods:** A literature search was conducted using different electronic databases. Specific terms were used for the database search, which spanned the years 1990 to 2008. The search was augmented by using the option of “related articles” as well as by hand searching of references and relevant journals. Relevant studies were selected according to predetermined inclusion and exclusion criteria. Agreement between reviewers was determined by using Cohen kappa coefficients. **Results:** The initial database search yielded 8,216 relevant titles. Following the filtering process, 19 studies were finally selected. No study directly compared the incidence of prosthodontic complications of complete implant-supported metal-ceramic versus metal-acrylic resin fixed prostheses in the completely edentulous patient. Studies of metal-ceramic prostheses were scarce and short term. **Conclusion:** Metal-acrylic resin complete implant fixed prostheses presented with various prosthodontic complications after long-term function. The most frequent complications were veneer fracture and material wear. *Int J Oral Maxillofac Implants* 2011;26:304–318

**Key words:** edentulous arch, implant fixed prosthesis, meta-analysis, prosthodontic complications, screw, veneer

<sup>1</sup>Postgraduate Student, Department of Fixed Prosthesis and Implant Prosthodontics, School of Dentistry, Aristotle University of Thessaloniki, Greece.

<sup>2</sup>Assistant Professor, Department of Fixed Prosthesis and Implant Prosthodontics, School of Dentistry, Aristotle University of Thessaloniki, Greece.

<sup>3</sup>Statistician, DCS Company, Thessaloniki, Greece.

<sup>4</sup>Professor Emeritus, Department of Fixed Prosthesis and Implant Prosthodontics, School of Dentistry, Aristotle University of Thessaloniki, Greece.

**Correspondence to:** Dr Haralampos P. Petridis, Department of Fixed Prosthesis, and Implant Prosthodontics, School of Dentistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. Fax: +30-2310999575. Email: Lpetridi@dent.auth.gr

*This material was presented at the Annual Congress of the European Prosthodontic Association, Innsbruck, Austria, October 1 to 3, 2009.*

The main objective in the treatment of edentulous patients with osseointegrated implants is either to avoid removable complete dentures by placement of complete implant-supported fixed prostheses (IFDPs) or to improve the retention and stability of removable complete dentures.<sup>1</sup> The earliest implant studies<sup>2–8</sup> followed patients treated with metal-acrylic resin complete IFDPs<sup>9</sup> with distal cantilevers, principally in the mandible. These restorations consisted of denture teeth connected to a metal framework with acrylic resin and were attached with screws to six implants placed between the mental foramina. The same prosthetic design is being used today on four to six implants in the mandible.<sup>1</sup>

As implant dentistry evolved, a variety of prosthetic designs associated with implant prostheses was introduced. In addition, the number of patients asking

for implant-supported reconstructions has increased considerably over the past few years,<sup>10</sup> and many patients receiving implants are now treated with metal-ceramic complete IFDPs.<sup>9</sup> A metal-ceramic IFDP consists of a ceramic layer bonded to a cast metal framework that can be cemented to transmucosal abutments or secured with prosthetic retention screws.<sup>11</sup>

Clinical research has mainly focused either on implant survival or on biologic and technical complications in partial edentulism.<sup>12-20</sup> The incidence of prosthodontic complications of complete IFDPs in the edentulous arch has been addressed to only a minor extent. No comparisons have been made between the incidence of prosthodontic complications of metal-ceramic versus metal-acrylic resin IFDPs.

The purpose of this study was to systematically review clinical studies of prosthodontic complication rates of IFDPs in edentulous patients after an observation period of at least 5 years.

## METHODS AND MATERIALS

### Search Strategy

The literature search was conducted by two individuals (TB, HP) using different electronic databases (MEDLINE/PubMed, the Cochrane Register of Randomized Controlled Trials, and the Database of Abstracts of Reviews of Effects) for English-language clinical studies reporting on prosthodontic complications of metal-ceramic and metal-resin IFDPs in the edentulous arch. Prosthodontic complications included framework/veneering material fractures, loosening of the prosthetic screw and/or abutment screw, fracture of the prosthetic screw and/or abutment screw, esthetic deficiencies, and material wear. The search terms that were used, alone or in combination, were "implant fixed prostheses," "prosthodontic complications," "technical complications," "mechanical complications," "screw complications," "edentulous arch," "metal framework fracture," "acrylic veneer fracture," "ceramic veneer fracture," "edentulous mandible," and "edentulous maxilla." The search covered a time span between January 1990 and December 2008. The option of "related articles" was also used. Review articles, as well as references from different studies, were also used to identify relevant articles. Hand searching for the time span between January 1990 and December 2008 was conducted on the following journals: *Journal of Prosthetic Dentistry*, *International Journal of Prosthodontics*, *International Journal of Oral & Maxillofacial Implants*, *Implant Dentistry*, and *Clinical Oral Implants Research*.

### Selection of Studies

The review process consisted of two phases. During the first phase, the titles, abstracts, and/or full texts were reviewed by the two reviewers together. Initially, titles were screened for relevance, and the abstracts of the relevant articles were obtained. The articles obtained were screened using the following exclusion and inclusion criteria. Articles that were laboratory studies, case reports, technical articles, or were in a language other than English or had no English-language abstract were excluded. Clinical studies reporting on prosthodontic complications of IFDPs in the edentulous arch, with either a prospective or a retrospective design and patient follow-up, were included.

Any disagreement was resolved by discussion; in case of doubt, the full text of the article was obtained. Hand searching of the selected journals, as well as searching of the references of the selected studies, was also implemented at this point.

The selected full texts were further screened independently by the two reviewers in a second phase of review using the following inclusion criteria:

1. Mean follow-up period of at least 5 years
2. Clinical examination of patients at the follow-up visit
3. Details reported on the materials used for the prosthetic reconstruction
4. Number of patients stated
5. Study outcome stated as prosthodontic complications and related to follow-up time


Various potential factors influencing complications that were examined were:

1. Presence of parafunctional habits
2. Number of implants supporting the IFDPs
3. Opposing arch condition
4. Type of suprastructure retention (screw versus cement)

Interviewer agreement was determined using Cohen kappa coefficients.

Next, the final included studies that passed the second phase in the review process were classified according to the strength of evidence into four categories according to Jökstad et al<sup>21</sup>:

1. A1: controlled clinical trial with patient randomization (RCT)
2. A2: controlled clinical trial with split-mouth randomization (split-mouth RCT)
3. B: prospective controlled trial without randomization (CCT)
4. C: clinical studies with different designs than categories A and B (retrospective, case series, etc)



**Fig 1** Search strategy.

## Data Extraction

Data of the final studies were tabulated for the following prosthodontic complications: veneer fracture, loosening of the prosthetic screw and/or abutment screw, fracture of the prosthetic screw and/or abutment screw, framework fracture, esthetic deficiencies, and material wear. The incidence of each prosthodontic complication mentioned earlier was finally calculated in relation to time. In studies where only the minimum follow-up time was mentioned, that interval was used to measure the total exposure time of the restorations. In cases of multiple publications following the same cohort of patients, the study with the longest follow-up was included.

## Statistical Analysis

Complication rates for IFDPs were calculated by dividing the total number of events (complications) in the numerator by the total IFDPs' exposure time in years in the denominator. The total number of events

(numerator) was extracted directly from the publication. The exposure time (denominator) was calculated by multiplying the mean follow-up time by the number of IFDPs available for statistical analysis. The mean follow-up was extracted directly from the articles. IFDPs available for the analysis were defined as all the prostheses from which information was available relative to the issues considered.

Poisson distribution was considered for the number of events per variable under examination. Five-, 10-, and 15-year survival proportions (with the corresponding 95% confidence intervals [CIs]) were calculated via the relationship between the event rate and the survival function  $S(t) = \exp(-t \times \text{event rate})$ , assuming a constant event rate. The 95% CI was calculated with the aid of Poisson regression analysis with a logarithmic link function. It should be mentioned that Poisson regression is appropriate for rate data, where the rate is a count of events occurring to a unit of observations divided by a measure of exposure (events per unit time). If heterogeneity ( $I^2$  value with  $P < .05$ ) among papers' estimates per variable was observed, a random effect model was considered for the summary estimates. STATA software (Statacorp) was used for Poisson regression.

## RESULTS

Figure 1 shows the process used to identify the studies finally included from the initial yield of 8,216 titles. Initial analysis of titles led to 197 abstracts. Seventy-nine abstracts were excluded, so 116 full texts were obtained. Twenty-six studies were retrieved from journal hand searching and references; therefore, 142 full texts were screened for inclusion/exclusion criteria in the first phase. Of these, 53 studies were excluded and 89 studies passed the first review phase.

In the second review phase, 58 studies<sup>22-79</sup> were excluded and 31 studies<sup>4-8,80-104</sup> were deemed to have met the inclusion criteria. After studies of the same cohorts were excluded, 19 studies<sup>80-98</sup> were finally selected for analysis. The interreviewer agreement for the five inclusion criteria during the second review phase ranged from "substantial" to "perfect" (kappa: 0.61 to 1.0;  $P < .001$ ). The studies that were rejected during the second review phase are shown in Table 1.

All selected studies<sup>80-98</sup> had been published in the last 18 years. The publication dates ranged from 1990 to 2008, with half of the studies published in the last 10 years. No study directly compared the incidence of prosthodontic complications of metal-ceramic versus metal-acrylic resin IFDPs in completely edentulous patients. Almost half of the studies were classified as

**Table 1 Studies Excluded During the Second Phase of Review and Reasons for Exclusion**

| Studies  | Reason for exclusion   |
|--|--|
| Köndell et al, 1988 <sup>22</sup> ; Jemt, 1991 <sup>23</sup> ; Arvidson et al, 1992 <sup>24</sup> ; Tolman and Laney, 1992 <sup>25</sup> ; Jemt and Linden, 1992 <sup>26</sup> ; Naert et al, 1992 <sup>27</sup> ; Walton and MacEntee, 1993 <sup>28</sup> ; Carlson and Carlsson, 1994 <sup>29</sup> ; Hulterström and Nilsson, 1994 <sup>30</sup> ; Gunne et al, 1995 <sup>31</sup> ; Rubenstein, 1995 <sup>32</sup> ; Walton and MacEntee, 1997 <sup>33</sup> ; Behr et al, 1998 <sup>34</sup> ; Kaptein et al, 1999 <sup>35</sup> ; Krekmanov et al, 2000 <sup>36</sup> ; Örtorp and Jemt, 2000 <sup>37</sup> ; Zitzmann and Marinello, 2000 <sup>38</sup> ; De Bruyn et al, 2000 <sup>39</sup> ; Yi et al, 2001 <sup>40</sup> ; Moberg et al, 2001 <sup>41</sup> ; Engquist et al, 2002 <sup>42</sup> ; Örtorp and Jemt, 2002 <sup>43</sup> ; Duncan et al, 2003 <sup>44</sup> ; Henry et al, 2003 <sup>45</sup> ; Raghoobar et al, 2003 <sup>46</sup> ; Maló et al, 2003 <sup>47</sup> ; Göthberg et al, 2003 <sup>48</sup> ; Engstrand et al, 2003 <sup>49</sup> ; Bergkvist et al, 2004 <sup>50</sup> ; Romeo et al, 2004 <sup>51</sup> ; Preiskel and Tsolka, 2004 <sup>52</sup> ; Friberg et al, 2005 <sup>53</sup> ; Hjalmarsson and Smedberg, 2005 <sup>54</sup> ; Maló et al, 2006 <sup>55</sup> ; Aparicio et al, 2006 <sup>56</sup> | Mean follow-up period < 5 y  |
| De Bruyn et al, 1999 <sup>57</sup> ; Hellden et al, 2003 <sup>58</sup> ; Rasmusson et al, 2005 <sup>59</sup> ; Åstrand et al, 2004 <sup>60</sup>   | Details on materials not reported  |
| Brånemark et al, 1995 <sup>61</sup> ; Keller, 1995 <sup>62</sup> ; Schnitman et al, 1997 <sup>63</sup> ; Eliasson et al, 2000 <sup>64</sup> ; Wennerberg et al, 2001 <sup>65</sup> ; Peñarrocha et al, 2007a <sup>66</sup>   | Prosthodontic complications not stated   |
| Brånemark et al, 1999 <sup>67</sup> ; Collaert and De Bruyn, 2002 <sup>68</sup> ; Peñarrocha et al, 2007b <sup>69</sup>  | Mean follow-up period < 5 y; Prosthodontic complications not stated                                    |
| Tolman and Laney, 1993 <sup>70</sup> ; Allen et al, 1997 <sup>71</sup> ; Balshi et al, 1997 <sup>72</sup>  | Mean follow-up period < 5 y; Details on materials not reported   |
| Shackleton et al, 1996 <sup>73</sup> ; Misch and Wang, 2003 <sup>74</sup>  | Mean follow-up period < 5 y; Details on materials not reported; Prosthodontic complications not stated |
| De Bruyn et al, 1997 <sup>75</sup>   | Mean follow-up period < 5 y; No clinical examination at follow-up visit                                |
| Keller et al, 1999 <sup>76</sup> ; Friberg et al, 2000 <sup>77</sup> ; Hedkvist et al, 2004 <sup>78</sup> ; Nelson et al, 2007 <sup>79</sup>   | Details on materials not reported; Prosthodontic complications not stated                              |

category C and seven were category A1 according to the strength of the evidence,<sup>21</sup> and most were implemented in a university setting. The studies included a total of 944 patients with an age range of 28 to 93 years. The demographics and designs of the included studies are depicted in Table 2.

The studies reported on various commercially available implant systems. Most studies used an external-connection implant system (Nobel Biocare), and only four used an internal-connection implant system. No studies of metal-ceramic IFDPs fulfilled the criteria for inclusion in the analysis. All the finally included studies, therefore, reported on complications with screw-retained metal-acrylic resin IFDPs. A total of 998 IFDPs was observed over a minimum period of 5 years up to a maximum period of 23 years. The mean observation times ranged between 5 and 21.4 years. The majority of IFDPs were placed in the mandible. The information on the IFDPs placed is presented in Table 3.

All the prosthodontic complications related to suprastructure components are presented in Tables 4 to 11. Veneer fractures represented the most frequent prosthodontic complication; they were reported in

14 of the 19 included studies. The statistical analysis revealed estimated cumulative rates of veneer fractures over an observation period of 5, 10, and 15 years of 30.6%, 51.9%, and 66.6%, respectively (Table 4). The estimated rates of abutment and prosthetic screw loosening after 15 years were 13.4% and 15%, respectively (Tables 5 and 7). The estimated rates of abutment and prosthetic screw fracture after 15 years were 6.3% and 11.7%, respectively (Tables 6 and 8). The estimated rates for framework fractures, material wear, and esthetic deficiencies during the same follow-up period were 8.8%, 43.5%, and 9%, respectively (Tables 9 to 11).

The analysis of various factors potentially influencing complications did not produce any results. The final papers did not include any cement-retained IFDPs, and the presence of parafunctional habits was not considered. The number of implants supporting the IFDPs was fairly uniform throughout the studies and typically ranged from four to six. As for the potential effect of the condition of the opposing arch, only one study<sup>90</sup> reported weak evidence that more maintenance was needed for patients with an opposing IFDP.

**Table 2 Study Design and Demographics of Included Studies**

| Study                                       | Category of evidence (study design) | Gender |     | No. of patients |        |            | Age (y) |                                       |                                       | Setting    |
|---|-------------------------------------|--------|-----|-----------------|--------|------------|---------|---------------------------------------|---------------------------------------|------------|
|   |                                     | M      | F   | Planned         | Actual | % dropouts | Range   | Mean                                  | SD                                    |            |
| Johansson and Palmqvist, 1990 <sup>80</sup> | C (R)                               | 22     | 25  | 47              | 47     | 0          | NR      | NR                                    | NR                                    | University |
| Kallus and Bessing, 1994 <sup>81</sup>      | C (R)                               | 14     | 36  | 50              | 50     | 0          | NR      | 66.1 (M)<br>68.2 (F)                  | NR                                    | Private    |
| Henry et al, 1995 <sup>82</sup>             | C (P)                               | NR     | NR  | 15              | 15     | 0          | 29–73   | 50                                    | NR                                    | University |
| Watson and Davis, 1996 <sup>83</sup>        | B (P)                               | NR     | NR  | 20              | NR     | NR         | NR      | NR                                    | NR                                    | University |
| Friberg et al, 1997 <sup>84</sup>           | A2 (P)                              | 49     | 54  | 102             | 83     | 18.6       | 33–83   | 59                                    | NR                                    | University |
| Makkonen et al, 1997 <sup>85</sup>          | C (P)                               | 6      | 7   | 13              | 10     | 23.1       | 39–69   | 50                                    | 10                                    | University |
| Arvidson et al, 1998 <sup>86</sup>          | A1 (P)                              | 43     | 64  | 107             | 91     | 15         | NR      | NR                                    | NR                                    | NR         |
| Tinsley et al, 2001 <sup>87</sup>           | A1 (P)                              | NR     | NR  | 21              | NR     | NR         | 37–80   | NR                                    | NR                                    | NR         |
| Jemt et al, 2002 <sup>88</sup>              | A1 (P)                              | 33     | 25  | 58              | 50     | 13.8       | 38–74   | 60                                    | NR                                    | Private    |
| Murphy et al, 2002 <sup>89</sup>            | B (P)                               | 18     | 8   | 26              | 26     | 0          | NR      | 60                                    | NR                                    | University |
| Davis et al, 2003 <sup>90</sup>             | C (R)                               | 8      | 29  | 37              | 37     | 0          | 36–71   | 56                                    | NR                                    | NR         |
| Ekelund et al, 2003 <sup>91</sup>           | C (P)                               | 14     | 33  | 47              | 30     | 36.2       | 34–67   | 53.4                                  | NR                                    | University |
| Attard and Zarb, 2004 <sup>92</sup>         | A1 (P)                              | 10     | 36  | 46              | 31     | 32.6       | 28–69   | 50                                    | 11.6                                  | University |
| Engfors et al, 2004 <sup>93</sup>           | C (R)                               | 112    | 136 | 248             | 164    | 33.9       | 41–93   | Study group 83.1;<br>control group 65 | Study group 2.9;<br>control group 9.6 | Private    |
| Örtoft and Jemt, 2004 <sup>94</sup>         | A1 (P)                              | 62     | 64  | 126             | 101    | 19.8       | 41–88   | 66.5                                  | 10.8                                  | Private    |
| Jemt and Johansson, 2006 <sup>95</sup>      | C (P)                               | 48     | 28  | 76              | 28     | 63.2       | 32–75   | 60.1                                  | 11.6                                  | University |
| Örtoft and Jemt, 2006 <sup>96</sup>         | A1 (P)                              | 104    | 104 | 208             | 112    | 46.2       | 35–87   | NR                                    | NR                                    | Private    |
| Fischer et al, 2008 <sup>97</sup>           | A1 (P)                              | 8      | 16  | 24              | 23     | 4.2        | NR      | 64                                    | NR                                    | University |
| Purcell et al 2008 <sup>98</sup>            | C (R)                               | 14     | 32  | 46              | 46     | 0.0%       | NR      | 59                                    | NR                                    | NR         |

NR = not reported; R = retrospective; P = prospective.

## DISCUSSION

Systematic reviews differ from other types of reviews in that they adhere to a strict scientific protocol to make them more comprehensive, to eliminate the likelihood of bias, and to provide more reliable results upon which to draw conclusions and make decisions. Rather than reflecting the views of the authors or being based on only a (possibly biased) selection of the published literature, they represent a comprehensive summary of the available evidence, with strict inclusion and ex-

clusion criteria. Methodologies for undertaking systematic reviews have been described.<sup>105,106</sup> The gold standard for systematic reviews is to include RCTs, which are more likely to provide reliable information than other sources of evidence. The majority of the studies included in this review were prospective. Almost half of the studies were classified as category C and seven as A1 (RCTs).

Two reviewers were used to ensure that the selection of studies for inclusion and data extraction could be performed independently and to increase the chance that errors would be detected. Interexaminer

Table 3 Information on IFDPs in the Selected Studies

| Study                                       | Implant system | Type of connection | Planned no. of implants per prosthesis | Type of prosthesis | Opposing dentition           | No. of max prostheses |        |           | No. of mand prostheses |        |           | Total no. of prostheses |        |           | Follow-up (y) |      |
|---|----------------|--------------------|--|--------------------|------------------------------|-----------------------|--------|-----------|------------------------|--------|-----------|-------------------------|--------|-----------|---------------|------|
|   |                |                    |  |                    |                              | Planned               | Actual | % dropout | Planned                | Actual | % dropout | Planned                 | Actual | % dropout | Range         | Mean |
| Johansson and Palmqvist, 1990 <sup>80</sup> | Nobel Biocare  | External           | NR                                     | MR                 | NR                           | 18                    | 18     | 0         | 31                     | 31     | 0         | 49                      | 49     | 0         | 3-9           | 5.2  |
| Kallus and Bessing, 1994 <sup>81</sup>      | Nobel Biocare  | External           | 4-6                                    | MR                 | NR                           | 16                    | 16     | 0         | 34                     | 34     | 0         | 50                      | 50     | 0         | 5.5-5.9       | 5.4  |
| Henry et al, 1995 <sup>82</sup>             | Nobel Biocare  | External           | 6                                      | MR                 | 12 CD                        | NA                    | NA     | NA        | 15                     | 15     | 0         | 15                      | 15     | 0         | NA            | 10   |
| Watson and Davis, 1996 <sup>83</sup>        | Nobel Biocare  | External           | 4-6                                    | MR                 | CD                           | NA                    | NA     | NA        | 20                     | 20     | 0         | 20                      | 20     | 0         | NA            | 5    |
| Friberg et al, 1997 <sup>84</sup>           | Nobel Biocare  | External           | NR                                     | MR                 | NR                           | 33                    | NR     | NR        | 69                     | NR     | NR        | 102                     | 83     | 18.6      | NA            | 5    |
| Makkinen et al, 1997 <sup>85</sup>          | Astra          | Internal           | 5-6                                    | MR                 | CD                           | NA                    | NA     | NA        | 13                     | 10     | 23.1      | 13                      | 10     | 23.1      | NA            | 5    |
| Arvidson et al, 1998 <sup>86</sup>          | Astra          | Internal           | 4-6                                    | MR                 | NR                           | NA                    | NA     | NA        | 107                    | 91     | 15.0      | 107                     | 91     | 15.0      | NA            | 5    |
| Tinsley et al, 2001 <sup>87</sup>           | Calcitek       | External           | 5                                      | MR                 | 16 CD, 5 other               | NA                    | NA     | NA        | 21                     | 21     | 0         | 21                      | 21     | 0         | NA            | 5    |
| Jemt et al, 2002 <sup>88</sup>              | Nobel Biocare  | External           | > 5                                    | MR                 | NR                           | 58                    | 50     | 13.8      | NA                     | NA     | NA        | 58                      | 50     | 13.8      | NA            | 5    |
| Murphy et al, 2002 <sup>89</sup>            | Astra          | Internal           | 5                                      | MR                 | CD                           | NA                    | NA     | NA        | 26                     | 26     | 0         | 26                      | 26     | 0         | NA            | 5    |
| Davis et al, 2003 <sup>90</sup>             | Nobel Biocare  | External           | 5-6                                    | MR                 | 22 CD, 6 IP, 9 ND            | 8                     | 8      | 0         | 29                     | 29     | 0         | 37                      | 37     | 0         | NA            | 5    |
| Ekelund et al, 2003 <sup>91</sup>           | Nobel Biocare  | External           | 5-6                                    | MR                 | 13 IP, 34 CD                 | NA                    | NA     | NA        | 47                     | 30     | 36.2      | 47                      | 30     | 36.2      | 20-23         | 21.4 |
| Attard and Zarb, 2004 <sup>92</sup>         | Nobel Biocare  | External           | 4-6                                    | MR                 | 40 CD, 3 ND                  | 4                     | NR     | NR        | 41                     | NR     | NR        | 45                      | 38     | 15.6      | 11-15         | 11   |
| Engfors et al, 2004 <sup>93</sup>           | Nobel Biocare  | External           | 4-8 max/4-6 mand                       | MR                 | NR                           | 95                    | 64     | 32.6      | 162                    | 103    | 36.4      | 257                     | 167    | 35        | NA            | 5    |
| Örtorp and Jemt, 2004 <sup>94</sup>         | Nobel Biocare  | External           | 4-8 max/4-6 mand                       | MR                 | 41 CD, 25 IP, 63 M           | 54                    | 40     | 25.9      | 75                     | 61     | 18.6      | 129                     | 101    | 21.7      | NA            | 5    |
| Jemt and Johansson, 2006 <sup>95</sup>      | Nobel Biocare  | External           | 6 mean                                 | MR                 | 1 CD, 9 RPD, 18 IP           | 76                    | 28     | 63.2      | NA                     | NA     | NA        | 76                      | 28     | 63.2      | NA            | 15   |
| Örtorp and Jemt, 2006 <sup>96</sup>         | Nobel Biocare  | External           | 4-6                                    | MR                 | 154 CD, 14 IP, 40 M          | NA                    | NA     | NA        | 208                    | 112    | 46.2      | 208                     | 112    | 46.2      | NA            | 10   |
| Fischer et al, 2008 <sup>97</sup>           | Strumann       | Internal           | 5-6                                    | MR                 | 1 CD, 6 RPD, 1 IP, 8 ND, 6 M | 24                    | 23     | 4.2       | NA                     | NA     | NA        | 24                      | 23     | 4.2       | NA            | 5    |
| Purcell et al, 2008 <sup>98</sup>           | Nobel Biocare  | External           | 5-6                                    | MR                 | CD                           | NA                    | NA     | NA        | 46                     | 46     | 0         | 46                      | 46     | 0         | 5-9.7         | 7.9  |

NR = not reported; NA = not applicable; MC = metal-ceramic; MR = metal-acrylic resin; CD = complete denture; RPD = removable partial denture; IP = implant prosthesis; ND = natural dentition; M = mixed; max = maxilla; mand = mandible.



**Table 4 Veneer Fracture**

| Study                                       | No. of prostheses | Mean follow-up (y) | Total exposure time (y) | No. of veneer fracture events | Estimated rate* |
|---|-------------------|--------------------|-------------------------|-------------------------------|-----------------|
| Johansson and Palmqvist, 1990 <sup>80</sup> | 49                | 5.2                | 254.8                   | 11                            | 4.3             |
| Henry et al, 1995 <sup>82</sup>             | 15                | 10                 | 150                     | 23                            | 15.3            |
| Watson and Davis, 1996 <sup>83</sup>        | 20                | 5                  | 100                     | 4                             | 4.0             |
| Friberg et al, 1997 <sup>84</sup>           | 83                | 5                  | 415                     | 7                             | 1.7             |
| Jemt et al, 2002 <sup>88</sup>              | 50                | 5                  | 250                     | 23                            | 9.2             |
| Murphy et al, 2002 <sup>89</sup>            | 26                | 5                  | 130                     | 4                             | 3.1             |
| Davis et al, 2003 <sup>90</sup>             | 37                | 5                  | 185                     | 60                            | 32.4            |
| Ekelund et al, 2003 <sup>91</sup>           | 30                | 21.4               | 642                     | 5                             | 0.8             |
| Engfors et al, 2004 <sup>93</sup>           | 167               | 5                  | 835                     | 33                            | 3.9             |
| Örtorp and Jemt, 2004 <sup>94</sup>         | 101               | 5                  | 505                     | 38                            | 7.5             |
| Jemt and Johansson, 2006 <sup>95</sup>      | 28                | 15                 | 420                     | 158                           | 37.6            |
| Ortorp and Jemt, 2006 <sup>96</sup>         | 112               | 10                 | 1,120                   | 53                            | 4.7             |
| Fischer et al, 2008 <sup>97</sup>           | 23                | 5                  | 115                     | 30                            | 26.1            |
| Purcell et al, 2008 <sup>98</sup>           | 46                | 7.9                | 363.4                   | 28                            | 7.7             |
| <b>Summary estimates<sup>†</sup></b>        | <b>Rate (%)</b>   | <b>95% CI</b>      |                         |                               |                 |
| Based on random effect                      | 7.3               | 3.9–13.3           |                         |                               |                 |
| Cumulative 5-y complication rates           | 30.6              | 17.7–48.6          |                         |                               |                 |
| Cumulative 10-y complication rates          | 51.9              | 32.3–75.5          |                         |                               |                 |
| Cumulative 15-y complication rates          | 66.6%             | 44.3–86.4          |                         |                               |                 |

\*Per 100 prostheses-years.

†Heterogeneity:  $I^2 = 97.443$ ;  $P < .001$ .**Table 5 Abutment Screw Loosening**

| Study                                  | No. of prostheses | Mean follow-up (y) | Total exposure time (y) | No. of abutment screw loosening events | Estimated rate* |
|--|-------------------|--------------------|-------------------------|--|-----------------|
| Kallus and Bessing, 1994 <sup>81</sup> | 50                | 5.4                | 270                     | 10                                     | 3.7             |
| Watson and Davis, 1996 <sup>83</sup>   | 20                | 5                  | 100                     | 6                                      | 6.0             |
| Arvidson et al, 1998 <sup>86</sup>     | 91                | 5                  | 455                     | 0                                      | 0               |
| Tinsley et al, 2001 <sup>87</sup>      | 21                | 5                  | 105                     | 0                                      | 0               |
| Murphy et al, 2002 <sup>89</sup>       | 26                | 5                  | 130                     | 2                                      | 1.5             |
| Davis et al, 2003 <sup>90</sup>        | 37                | 5                  | 185                     | 4                                      | 2.2             |
| Engfors et al, 2004 <sup>93</sup>      | 167               | 5                  | 835                     | 1                                      | 0.1             |
| Ortorp and Jemt, 2004 <sup>94</sup>    | 101               | 5                  | 515                     | 0                                      | 0               |
| Jemt and Johansson, 2006 <sup>95</sup> | 28                | 15                 | 420                     | 0                                      | 0               |
| Ortorp and Jemt, 2006 <sup>96</sup>    | 112               | 10                 | 1,120                   | 53                                     | 4.7             |
| Purcell et al, 2008 <sup>98</sup>      | 46                | 7.9                | 363.4                   | 5                                      | 1.4             |
| <b>Summary estimates<sup>†</sup></b>   | <b>Rate</b>       | <b>95% CI</b>      |                         |  |                 |
| Based on random effects                | 1.0               | 0.5–1.5            |                         |  |                 |
| Cumulative 5-y complication rates      | 4.7               | 2.3–7.1            |                         |  |                 |
| Cumulative 10-y complication rates     | 9.2               | 4.5–13.7           |                         |  |                 |
| Cumulative 15-y complication rates     | 13.4              | 6.6–19.8           |                         |  |                 |

\*Per 100 prostheses-years. †Heterogeneity:  $I^2 = 86.345$ ;  $P < .001$ .

**Table 6** Abutment Screw Fracture

| Study                                       | No. of prostheses | Mean follow-up (y) | Total exposure time (y) | No. of abutment screw fracture events | Estimated rate* |
|---|-------------------|--------------------|-------------------------|---------------------------------------|-----------------|
| Johansson and Palmqvist, 1990 <sup>80</sup> | 49                | 5.2                | 254.8                   | 3                                     | 1.2             |
| Kallus and Bessing, 1994 <sup>81</sup>      | 50                | 5.4                | 270                     | 0                                     | 0               |
| Henry et al, 1995 <sup>82</sup>             | 15                | 10                 | 150                     | 8                                     | 5.3             |
| Watson and Davis, 1996 <sup>83</sup>        | 20                | 5                  | 100                     | 5                                     | 5.0             |
| Friberg et al, 1997 <sup>84</sup>           | 83                | 5                  | 415                     | 1                                     | 0.2             |
| Arvidson et al, 1998 <sup>86</sup>          | 91                | 5                  | 455                     | 0                                     | 0               |
| Tinsley et al, 2001 <sup>87</sup>           | 21                | 5                  | 105                     | 2                                     | 1.9             |
| Jemt et al, 2002 <sup>88</sup>              | 50                | 5                  | 250                     | 0                                     | 0               |
| Murphy et al, 2002 <sup>89</sup>            | 26                | 5                  | 130                     | 1                                     | 0.8             |
| Davis et al, 2003 <sup>90</sup>             | 37                | 5                  | 185                     | 8                                     | 4.3             |
| Attard and Zarb, 2004 <sup>92</sup>         | 38                | 11                 | 418                     | 25                                    | 6.0             |
| Engfors et al, 2004 <sup>93</sup>           | 167               | 5                  | 835                     | 1                                     | 0.1             |
| Ortorp and Jemt, 2004 <sup>94</sup>         | 101               | 5                  | 505                     | 0                                     | 0               |
| Jemt and Johansson, 2006 <sup>95</sup>      | 28                | 15                 | 420                     | 0                                     | 0               |
| Ortorp and Jemt, 2006 <sup>96</sup>         | 112               | 10                 | 1,120                   | 6                                     | 0.5             |
| Fischer et al, 2008 <sup>97</sup>           | 23                | 5                  | 115                     | 0                                     | 0               |
| Purcell et al, 2008 <sup>98</sup>           | 46                | 7.9                | 363.4                   | 2                                     | 0.5             |
| <b>Summary estimates<sup>†</sup></b>        | <b>Rate</b>       | <b>95% CI</b>      |                         |                                       |                 |
| Based on random effects                     | 0.4               | 0.2–0.7            |                         |                                       |                 |
| Cumulative 5-y complication rates           | 2.1               | 0.8–3.5            |                         |                                       |                 |
| Cumulative 10-y complication rates          | 4.3               | 1.6–6.8            |                         |                                       |                 |
| Cumulative 15-y complication rates          | 6.3               | 2.4–10.1           |                         |                                       |                 |

\*Per 100 prostheses-years. †Heterogeneity:  $I^2 = 68.992$ ;  $P < .001$ .

agreement ranged from substantial to perfect. Database searches were also augmented by hand searching to minimize selection bias.<sup>107</sup>

The exclusion of papers in languages other than English may have resulted in the loss of some papers and poses a disadvantage for two reasons: (1) the number of abstracts actually examined might have been limited if there were a substantial number of additional studies published in languages other than English; (2) the chance of bias may have been increased if the results of studies published in English differed systematically from those published in other languages. On the other hand, it is difficult to gain access to nonEnglish-language journals all over the world, and it is difficult to define the features of the peer-review processes of these journals. Moreover, when nonEnglish papers are selected, based on their abstracts, the contents must be translated, with the risk of interpretation problems.<sup>108</sup> One study<sup>109</sup> found little effect of the inclusion/exclusion of papers published in languages other than English on combined effect estimates in meta-analyses of RCTs.

No studies existed that directly compared the incidence of prosthodontic complications of metal-ceramic versus metal-acrylic resin complete IFDPs. Therefore, all the studies included in the present review examined metal-acrylic resin IFDPs. There were no studies following metal-ceramic IFDPs that also met the inclusion criteria of the second review phase and especially the mean follow-up period: nine studies<sup>27,29,33,35,38,39,50,51,56</sup> reported on metal-ceramic IFDPs but had a mean follow-up period between 1 and 3 years. This was an unexpected finding because metal-ceramic implant prostheses are now routinely used for the rehabilitation of both partially and completely edentulous patients.<sup>1</sup> This finding also warrants caution regarding the long-term rate of complications of metal-ceramic IFDPs. The follow-up time chosen was set at a minimum of 5 years, which could be considered adequate for at least short-term results. The mean follow-up times reported in the final studies permitted a long-term projection of complication rates up to 15 years of follow-up.

Technical complications are common in all forms of prosthetic dentistry<sup>18,110</sup> and often jeopardize the



**Table 7 Prosthetic Screw Loosening**

| Study                                  | No. of prostheses | Mean follow-up (y) | Total exposure time (y) | No. of prosthetic screw loosening events | Estimated rate* |
|--|-------------------|--------------------|-------------------------|--|-----------------|
| Kallus and Bessing, 1994 <sup>81</sup> | 50                | 5.4                | 270                     | 67                                       | 24.8            |
| Watson and Davis, 1996 <sup>83</sup>   | 20                | 5                  | 100                     | 1  | 1.0             |
| Makkonen et al, 1997 <sup>85</sup>     | 10                | 5                  | 50                      | 1  | 2.0             |
| Arvidson et al, 1998 <sup>86</sup>     | 91                | 5                  | 455                     | 0  | 0               |
| Tinsley et al, 2001 <sup>87</sup>      | 21                | 5                  | 105                     | 0  | 0               |
| Jemt et al, 2002 <sup>88</sup>         | 50                | 5                  | 250                     | 6  | 2.4             |
| Murphy et al, 2002 <sup>89</sup>       | 26                | 5                  | 130                     | 15                                       | 11.5            |
| Davis et al, 2003 <sup>90</sup>        | 37                | 5                  | 185                     | 3  | 1.6             |
| Ekelund et al, 2003 <sup>91</sup>      | 30                | 21.4               | 642                     | 25                                       | 3.9             |
| Engfors et al, 2004 <sup>93</sup>      | 167               | 5                  | 835                     | 1  | 0.1             |
| Ortorp and Jemt, 2004 <sup>94</sup>    | 101               | 5                  | 505                     | 0  | 0               |
| Jemt and Johansson, 2006 <sup>95</sup> | 28                | 15                 | 420                     | 0  | 0               |
| Ortorp and Jemt, 2006 <sup>96</sup>    | 112               | 10                 | 1,120                   | 2  | 0.2             |
| Fischer et al, 2008 <sup>97</sup>      | 23                | 5                  | 115                     | 2  | 1.7             |
| Purcell et al, 2008 <sup>98</sup>      | 46                | 7.9                | 363.4                   | 13                                       | 3.6             |

| Summary estimates <sup>†</sup>     | Rate | 95% CI   |
|------------------------------------|------|----------|
| Based on random effects            | 1.1  | 0.6–1.6  |
| Cumulative 5-y complication rates  | 5.3  | 2.8–7.7  |
| Cumulative 10-y complication rates | 10.3 | 5.6–14.8 |
| Cumulative 15-y complication rates | 15.0 | 8.2–21.3 |

\*Per 100 prostheses-years. †Heterogeneity:  $I^2 = 88.936$ ;  $P < .001$ .

function and/or esthetics of a given prosthesis. Metal-acrylic resin IFDPs presented with a varying frequency of different complications, with veneer fracture being the most frequent. Almost 70% of the prostheses presented with some form of veneer fracture after 15 years of service. Acrylic resin veneers require sufficient material thickness and support from their underlying frameworks to withstand forces in the oral cavity.<sup>111–114</sup> Veneer fractures may be caused by material failure, design issues, and/or technical errors.<sup>113</sup> Many of these factors can be controlled with technical excellence, but the high incidence of acrylic resin failures in prosthodontics<sup>18,110</sup> suggests that the problem cannot be eliminated completely. The incidence of veneer fracture versus the number of prostheses reviewed indicates that certain prostheses<sup>82,90,94,95,97</sup> presented with multiple veneer fractures, thereby confirming the role of technical errors as mentioned before. The inherent weakness of acrylic resin denture teeth was also evident in the frequency of wear. Almost half of the metal-acrylic resin IFDPs presented with material wear after 15 years. Different options were presented to slow the process of tooth wear,

including altering the denture tooth surface with amalgam or gold alloy or using porcelain denture teeth.<sup>98</sup> The frequency of both acrylic resin fractures and wear is influenced by such factors as the opposing dentition and the presence of parafunctional habits.<sup>115,116</sup> The effects of these factors were not considered in the results of the final papers in this review. The design of future studies should incorporate these variables. When acrylic resin veneer fractures or wear occur, the ability to remove and repair the prosthesis, as is the case with screw-retained metal-acrylic resin IFDPs, is a distinct advantage. However, the high frequency of these particular complications indicates the need to inform prospective implant patients of future maintenance requirements.

Screw-related complications are commonly reported in the dental literature.<sup>18,20,44,117</sup> Regardless of their design, implant screw joints are susceptible to screw loosening or fracture because of the magnitude and direction of oral forces and the strength limitations of the components. Various factors may contribute to screw complications: inadequate preload on the screws, overtightening of the screws leading to

**Table 8 Prosthetic Screw Fracture**

| Study                                       | No. of prostheses | Mean follow-up (y) | Total exposure time (y) | No. of prosthetic screw fracture events | Estimated rate* |
|---|-------------------|--------------------|-------------------------|---|-----------------|
| Johansson and Palmqvist, 1990 <sup>80</sup> | 49                | 5.2                | 254.8                   | 1                                       | 0.4             |
| Henry et al, 1995 <sup>82</sup>             | 15                | 10                 | 150                     | 2                                       | 1.3             |
| Arvidson et al, 1998 <sup>86</sup>          | 91                | 5                  | 455                     | 0                                       | 0               |
| Tinsley et al, 2001 <sup>87</sup>           | 21                | 5                  | 105                     | 0                                       | 0               |
| Jemt et al, 2002 <sup>88</sup>              | 50                | 5                  | 250                     | 0                                       | 0               |
| Murphy et al, 2002 <sup>89</sup>            | 26                | 5                  | 130                     | 2                                       | 1.5             |
| Davis et al, 2003 <sup>90</sup>             | 37                | 5                  | 185                     | 4                                       | 2.2             |
| Ekelund et al, 2003 <sup>91</sup>           | 30                | 21.4               | 642                     | 2                                       | 0.3             |
| Attard and Zarb, 2004 <sup>92</sup>         | 38                | 11                 | 418                     | 78                                      | 18.7            |
| Ortorp and Jemt, 2004 <sup>94</sup>         | 101               | 5                  | 505                     | 0                                       | 0               |
| Jemt and Johansson, 2006 <sup>95</sup>      | 28                | 15                 | 420                     | 1                                       | 0.2             |
| Fischer et al, 2008 <sup>97</sup>           | 23                | 5                  | 115                     | 0                                       | 0               |
| Purcell et al, 2008 <sup>98</sup>           | 46                | 7.9                | 363.4                   | 8                                       | 2.2             |
| <b>Summary estimates<sup>†</sup></b>        | <b>Rate</b>       | <b>95% CI</b>      |                         |   |                 |
| Based on random effects                     | 0.8               | 0.3–1.4            |                         |   |                 |
| Cumulative 5-y complication rates           | 4.1               | 1.5–6.6            |                         |   |                 |
| Cumulative 10-y complication rates          | 8.0               | 2.9–12.7           |                         |   |                 |
| Cumulative 15-y complication rates          | 11.7              | 4.4–18.5           |                         |   |                 |

\*Per 100 prostheses-years. Heterogeneity:  $I^2 = 86.739$ ;  $P < .001$ .

**Table 9 Framework Fracture**

| Study                                       | No. of prostheses | Mean follow-up (y) | Total exposure time (y) | No. of framework fracture events | Estimated rate* |
|---|-------------------|--------------------|-------------------------|----------------------------------|-----------------|
| Johansson and Palmqvist, 1990 <sup>80</sup> | 49                | 5.2                | 254.8                   | 1                                | 0.4             |
| Friberg et al, 1997 <sup>84</sup>           | 83                | 5                  | 415                     | 1                                | 0.2             |
| Makkonen et al, 1997 <sup>85</sup>          | 10                | 5                  | 50                      | 1                                | 2.0             |
| Arvidson et al, 1998 <sup>86</sup>          | 91                | 5                  | 455                     | 0                                | 0               |
| Tinsley et al, 2001 <sup>87</sup>           | 21                | 5                  | 105                     | 1                                | 0.9             |
| Murphy et al, 2002 <sup>89</sup>            | 26                | 5                  | 130                     | 0                                | 0               |
| Davis et al, 2003 <sup>90</sup>             | 37                | 5                  | 185                     | 7                                | 3.8             |
| Attard and Zarb, 2004 <sup>92</sup>         | 38                | 11                 | 418                     | 16                               | 3.8             |
| Engfors et al, 2004 <sup>93</sup>           | 167               | 5                  | 835                     | 2                                | 0.2             |
| Ortorp and Jemt, 2004 <sup>94</sup>         | 101               | 5                  | 505                     | 2                                | 0.4             |
| Jemt and Johansson, 2006 <sup>95</sup>      | 28                | 15                 | 420                     | 1                                | 0.2             |
| Ortorp and Jemt, 2006 <sup>96</sup>         | 112               | 10                 | 1,120                   | 32                               | 2.9             |
| Fischer et al, 2008 <sup>97</sup>           | 23                | 5                  | 115                     | 0                                | 0               |
| Purcell et al, 2008 <sup>98</sup>           | 46                | 7.9                | 363.4                   | 0                                | 0               |
| <b>Summary estimates<sup>†</sup></b>        | <b>Rate</b>       | <b>95% CI</b>      |                         |                                  |                 |
| Based on random effects                     | 0.6               | 0.3–1.0            |                         |                                  |                 |
| Cumulative 5-y complication rates           | 3.0               | 1.3–4.7            |                         |                                  |                 |
| Cumulative 10-y complication rates          | 6.0               | 2.6–9.3            |                         |                                  |                 |
| Cumulative 15-y complication rates          | 8.8               | 3.8–13.6           |                         |                                  |                 |

\*Per 100 prostheses-years. <sup>†</sup>Heterogeneity:  $I^2 = 73.456$ ;  $P < .001$ .

**Table 10 Esthetic Deficiencies**

| Study                                | No. of prostheses | Mean follow-up (y) | Total exposure time (y) | No. of esthetic deficiencies events | Estimated rate* |
|--------------------------------------|-------------------|--------------------|-------------------------|-------------------------------------|-----------------|
| Henry et al, 1995 <sup>82</sup>      | 15                | 10                 | 150                     | 1                                   | 0.7             |
| Ekelund et al, 2003 <sup>91</sup>    | 30                | 21.4               | 642                     | 3                                   | 0.5             |
| Engfors et al, 2004 <sup>93</sup>    | 167               | 5                  | 835                     | 7                                   | 0.8             |
| <b>Summary estimates<sup>†</sup></b> | <b>Rate</b>       | <b>95% CI</b>      |                         |                                     |                 |
| Based on fixed effects               | 0.6               | 0.2–1.0            |                         |                                     |                 |
| Cumulative 5-y complication rates    | 3.1               | 1.2–5.0            |                         |                                     |                 |
| Cumulative 10-y complication rates   | 6.1               | 2.4–9.7            |                         |                                     |                 |
| Cumulative 15-y complication rates   | 9.0               | 3.6–14.1           |                         |                                     |                 |

\*Per 100 prostheses-years. †Heterogeneity:  $I^2 = 0.000$ ;  $P = .278$

**Table 11 Material Wear**

| Study                                       | No. of prostheses | Mean follow-up (y) | Total exposure time (y) | No. of material wear events | Estimated rate* |
|---|-------------------|--------------------|-------------------------|-----------------------------|-----------------|
| Johansson and Palmqvist, 1990 <sup>80</sup> | 49                | 5.2                | 254.8                   | 3                           | 1.2             |
| Henry et al, 1995 <sup>82</sup>             | 15                | 10                 | 150                     | 1                           | 0.7             |
| Tinsley et al, 2001 <sup>87</sup>           | 21                | 5                  | 105                     | 2                           | 1.9             |
| Murphy et al, 2002 <sup>89</sup>            | 26                | 5                  | 130                     | 26                          | 20.0            |
| Jemt and Johansson, 2006 <sup>95</sup>      | 28                | 15                 | 420                     | 16                          | 3.8             |
| Purcell et al, 2008 <sup>98</sup>           | 46                | 7.9                | 363.4                   | 24                          | 6.6             |
| <b>Summary estimates<sup>†</sup></b>        | <b>Rate</b>       | <b>95% CI</b>      |                         |                             |                 |
| Based on random effects                     | 3.8               | 1.5–9.1            |                         |                             |                 |
| Cumulative 5-y complication rates           | 17.3              | 7.4–36.7           |                         |                             |                 |
| Cumulative 10-y complication rates          | 31.6              | 14.2–59.9          |                         |                             |                 |
| Cumulative 15-y complication rates          | 43.5              | 20.5–74.6          |                         |                             |                 |

\*Based on 100 prostheses-years. †Heterogeneity:  $I^2 = 91.029$ ;  $P < .001$ .

stripping and/or screw deformation, and/or occlusal overload from parafunction, occlusal interferences, or excessively long cantilevers.<sup>118,119</sup> In the present review, screw-related complications were rare in the majority of studies. Certain studies presented with a higher frequency of screw-related complications, thereby raising the total summary estimate. Abutment screw loosening and abutment screw fracture events were low, with the exception of three<sup>81,83,96</sup> and four<sup>82,83,90,92</sup> publications, respectively. The same held true for prosthetic screw loosening and fracture, where three studies<sup>81,89,92</sup> presented with a higher frequency of complications. The studies with the higher frequency of screw-related complications used an external-hex connection between the dental implants and prosthetic parts. Some of the authors<sup>81,89</sup> mentioned that hand-tightening was used instead of a calibrated torque instrument.

Fracture of the metal framework is a nonreversible complication that usually leads to a remake of the prosthesis. Framework fractures were present to only a minor extent in the majority of the studies in the present systematic review. However, four studies<sup>85,90,92,96</sup> reported relatively higher frequencies of framework fractures during the follow-up period. These four studies<sup>85,90,92,96</sup> described a number of reasons for the occurrence of framework fractures; the most common cited reasons were poor alloy choice and decreased cross-sectional dimension distal to the most posterior implant.<sup>92</sup> Most fractures occurred at the beginning of the cantilever arms.<sup>90</sup> Thus, it can be concluded that the cantilever arms should be kept as short as possible and the bulk of the framework increased around the last abutment. Special attention should be given to the selection of the alloy type, the framework design, and the height of the framework.<sup>120</sup>

Only three studies<sup>82,91,93</sup> reported on the frequency of esthetic deficiencies, and the 15-year rate reached 9%. No specific esthetic outcome was measured in these studies, but it was stated that prostheses had to be replaced because of esthetic reasons. This finding may reflect the gradual degradation and discoloration of acrylic denture teeth in the oral environment.<sup>121–123</sup>

One important issue that should be mentioned is the validity of combining the results of studies performed at different time periods. If one study begins many years prior to a second study, it is distinctly possible that the results of the two studies may differ simply because of changes in the standards of practice that occurred during the time period covered by the two studies.<sup>124</sup> This “learning curve” has also been described in a retrospective study of treatment costs associated with implant-supported mandibular prostheses in edentulous patients.<sup>125</sup> The publication dates of the studies selected for the present review ranged from 1990 to 2008, with half of the studies published in the last 10 years. Despite the different time periods of the studies, higher complication rates were not seen for earlier studies. In fact, some of the later studies<sup>90,95,97</sup> presented with higher complication rates, eg, veneer fracture, compared to earlier studies. This could be explained by the fact that few changes in the materials and fabrication techniques of metal–acrylic resin IFDPs have been made over time.

The majority of prostheses in this study were mandibular metal–acrylic resin IFDPs. Maxillary IFDPs may present with different biomechanical challenges compared to mandibular IFDPs, given that they are more often opposed by natural teeth or implants and therefore are subjected to higher loading forces. The study design and result reporting of the included studies did not permit a direct comparison of complication rates between maxillary and mandibular prostheses.

Maintenance for IFDPs can be time consuming and costly. The prospective implant patient should be informed not only about the expected outcome of the treatment but also about its limitations. For the informed consent to treatment to be valid, the patient must be made aware of the risks of the treatment, the complications that may arise, and the additional costs involved in correcting them.<sup>125</sup>

The literature suggests that, in the hands of experienced operators,<sup>6,23,92,100</sup> complications occur frequently enough to concern clinicians of lesser experience. The retrievability of IFDPs is therefore an important consideration in delivering high-quality, patient-based treatment outcomes.

## CONCLUSION

Complete metal–acrylic resin implant fixed dental prostheses presented with varying frequencies of complications over a period of 15 years. The most frequent complications were veneer fracture and material wear. Substantial amounts of chair time should be expected by the clinician following fabrication of an implant-supported restoration. More long-term studies are needed, especially regarding metal-ceramic complete implant fixed dental prostheses.

## REFERENCES

1. Mericske-Stern RD, Taylor TD, Belser U. Management of the edentulous patient. *Clin Oral Implants Res* 2000;11(suppl): 108–125.
2. Adell R, Lekholm U, Rockler B, Brånemark P-I. A 15-year study of osseointegrated implants in the treatment of the edentulous jaw. *Int J Oral Surg* 1981;10:387–416.
3. Brånemark P-I. Introduction to osseointegration. In: Brånemark P-I, Zarb A, Albrektsson T (eds). *Tissue-Integrated Prostheses: Osseointegration in Clinical Dentistry*. Chicago: Quintessence, 1985:11–76.
4. Zarb GA, Schmitt A. The longitudinal clinical effectiveness of osseointegrated dental implants: The Toronto study. Part I: Surgical results. *J Prosthet Dent* 1990;63:451–457.
5. Zarb GA, Schmitt A. The longitudinal clinical effectiveness of osseointegrated dental implants: The Toronto study. Part II: The prosthetic results. *J Prosthet Dent* 1990;64:53–61.
6. Zarb GA, Schmitt A. The longitudinal clinical effectiveness of osseointegrated dental implants: The Toronto study. Part III: Problems and complications encountered. *J Prosthet Dent* 1990;64:185–194.
7. Zarb GA, Schmitt A. Osseointegration and the edentulous predicament. The 10-year-old Toronto study. *Br Dent J* 1991; 170:439–444.
8. Zarb GA, Schmitt A. The edentulous predicament. I: A prospective study of the effectiveness of implant-supported fixed prostheses. *J Am Dent Assoc* 1996;127:59–65.
9. Simon H, Yanase RT. Terminology of implant prostheses. *Int J Oral Maxillofac Implants* 2003;18:539–543.
10. Bornstein MM, Halbritter S, Harnisch H, Weber H-P, Buser D. A retrospective analysis of patients referred for implant placement to a specialty clinic: Indications, surgical procedures and early failures. *Int J Oral Maxillofac Implants* 2008;23: 1109–1116.
11. Sadowsky SJ. The implant-supported prosthesis for the edentulous arch: Design considerations. *J Prosthet Dent* 1997;78:28–33.
12. Berglundh T, Persson L, Klinge B. A systematic review of the incidence of biological and technical complications in the implant dentistry reported in prospective longitudinal studies of at least 5 years. *J Clin Periodontol* 2002;29(suppl 3):197–212.
13. Brägger U, Aeschlimann S, Bürgin W, Hämmerle CHF, Lang NP. Biological and technical complications and failures with fixed partial dentures (FPD) on implants and teeth after four to five years of function. *Clin Oral Implants Res* 2001;12:26–34.
14. Eckert SE, Wollan PC. Retrospective review of 1170 endosseous implants placed in partially edentulous jaws. *J Prosthet Dent* 1998;79:415–421.

15. Esposito M, Hirsch J-M, Lekholm U, Thomsen P. Biological factors contributing to failures of osseointegrated oral implants. (I) Success criteria and epidemiology. *Eur J Oral Sci* 1998; 106:527–551.
16. Esposito M, Hirsch J-M, Lekholm U, Thomsen P. Biological factors contributing to failures of osseointegrated oral implants. (II) Etiopathogenesis. *Eur J Oral Sci* 1998;106:721–764.
17. Goodacre CJ, Kan JYK, Rungcharassaeng K. Clinical complications of osseointegrated implants. *J Prosthet Dent* 1999;81: 537–552.
18. Goodacre CJ, Bernal G, Rungcharassaeng K, Kan JYK. Clinical complications with implants and implant prostheses. *J Prosthet Dent* 2003;90:121–132.
19. Lang NP, Wilson TG, Corbet EF. Biological complications with dental implant: Their prevention, diagnosis and treatment. *Clin Oral Implants Res* 2000;11(suppl):146–155.
20. Pjetursson BE, Tan K, Lang NP, Brägger U, Egger M, Zwahlen M. A systematic review of the survival and complication rates of fixed partial dentures (FPDs) after an observation period of at least 5 years. I. Implant-supported FPDs. *Clin Oral Implants Res* 2004;15:625–642.
21. Jökstad A, Brägger U, Brunski JB, Carr A, Naert I, Wennerberg A. Quality of dental implants. *Int Dent J* 2003;53:409–443.
22. Köndell PÅ, Landt H, NordenramÅ, Carlsson B, Danielsson K. The tissue-integrated prosthesis in the treatment of edentulous patients. A follow-up study. *Swed Dent J* 1988;12:11–16.
23. Jemt T. Failures and complications in 391 consecutively inserted fixed prostheses supported by Brånemark implants in edentulous jaws: A study of treatment from the time of prosthesis placement to the first annual checkup. *Int J Oral Maxillofac Implants* 1991;6:270–276.
24. Arvidson K, Bystedt H, Frykholm A, von Konow L, Lothigius E. A 3-year clinical study of Astra dental implants in the treatment of edentulous mandibles. *Int J Oral Maxillofac Implants* 1992;7:321–329.
25. Tolman DE, Laney WR. Tissue-integrated prosthesis complications. *Int J Oral Maxillofac Implants* 1992;7:477–484.
26. Jemt T, Linden B. Fixed implant-supported prostheses with welded titanium frameworks. *Int J Periodontics Restorative Dent* 1992;12:177–184.
27. Naert I, Quirynen M, van Steenberghe D, Darius P. A study of 589 consecutive implants supporting complete fixed prostheses. Part II: Prosthetic aspects. *J Prosthet Dent* 1992;68: 949–956.
28. Walton JN, MacEntee MI. A retrospective study on the maintenance and repair of implant-supported prostheses. *Int J Prosthodont* 1993;6:451–455.
29. Carlson B, Carlsson GE. Prosthodontic complications in osseointegrated dental implant treatment. *Int J Oral Maxillofac Implants* 1994;9:90–94.
30. Hulterström M, Nilsson U. Cobalt-chromium as a framework material in implant-supported fixed prostheses: A 3-year follow up. *Int J Oral Maxillofac Implants* 1994;9:449–454.
31. Gunne J, Nystrom E, Kahnberg KE. Bone grafts and implants in the treatment of the severely resorbed maxillae: A 3-year follow-up of the prosthetic restoration. *Int J Prosthodont* 1995;8:38–45.
32. Rubenstein JE. Stereo laser-welded titanium implant frameworks: Clinical and laboratory procedures with a summary of 1-year clinical trials. *J Prosthet Dent* 1995;74:284–293.
33. Walton JN, MacEntee MI. A prospective study on the maintenance of implant prostheses in private practice. *Int J Prosthodont* 1997;10:453–458.
34. Behr M, Lang R, Leibrock A, Rosentritt M, Handel G. Complication rate with prosthodontic reconstructions on ITI and IMZ dental implants. Internationales Team für Implantologie. *Clin Oral Implants Res* 1998;9:51–58.
35. Kaptein ML, De Putter C, De Lange GL, Blijdorp PA. A clinical evaluation of 76 implant-supported superstructures in the composite grafted maxilla. *J Oral Rehabil* 1999;26:619–623.
36. Krekmanov L, Kahn M, Rangert B, Lindstrom H. Tilting of posterior mandibular and maxillary implants for improved prosthesis support. *Int J Oral Maxillofac Implants* 2000;15:405–414.
37. Örtorp A, Jemt T. Clinical experiences of CNC-milled titanium frameworks supported by implants in the edentulous jaw: 1-year prospective study. *Clin Implant Dent Relat Res* 2000;2:2–9.
38. Zitzmann NU, Marinello CP. Treatment outcomes of fixed or removable implant-supported prostheses in the edentulous maxilla. Part II: Clinical findings. *J Prosthet Dent* 2000;83:434–442.
39. De Bruyn H, Linden U, Collaert B, Björn AL. Quality of fixed restorative treatment on Brånemark implants. A 3-year follow-up study in private dental practices. *Clin Oral Implants Res* 2000;11:248–255.
40. Yi SW, Ericsson I, Kim CK, Carlsson GE, Nilner K. Implant-supported fixed prostheses for the rehabilitation of periodontally compromised dentitions: A 3-year prospective clinical study. *Clin Implant Dent Relat Res* 2001;3:125–134.
41. Moberg LE, Köndell PA, Sagulin GB, Bolin A, Heimdahl A, Gynther GW. Brånemark system and ITI dental implant system for treatment of mandibular edentulism. A comparative randomized study: 3-year follow up. *Clin Oral Implants Res* 2001; 12:450–461.
42. Engquist B, Åstrand P, Anzen B, et al. Simplified methods of implant treatment in the edentulous lower jaw. A controlled prospective study. Part I: One-stage versus two-stage surgery. *Clin Implant Dent Relat Res* 2002;4:93–103.
43. Örtorp A, Jemt T. Clinical experience of CNC-milled titanium frameworks supported by implants in the edentulous jaw: A 3-year interim report. *Clin Implant Dent Relat Res* 2002;4:104–109.
44. Duncan JP, Nazarova E, Vogiatzi T, Taylor TD. Prosthodontic complications in a prospective clinical trial of single-stage implants at 36 months. *Int J Oral Maxillofac Implants* 2003;18:561–565.
45. Henry PJ, van Steenberghe D, Blomback U, et al. Prospective multicenter study on immediate rehabilitation of edentulous lower jaws according to the Brånemark Novum protocol. *Clin Implant Dent Relat Res* 2003;5:137–142.
46. Raghoobar GM, Friberg B, Grunert I, Hobkirk JA, Tepper G, Wendelhag I. 3-year prospective multicenter study on one-stage implant surgery and early loading in the edentulous mandible. *Clin Implant Dent Relat Res* 2003;5:39–46.
47. Malo P, Rangert B, Nobre M. "All-on-Four" immediate-function concept with Brånemark system implants for completely edentulous mandibles: A retrospective clinical study. *Clin Implant Dent Relat Res* 2003;5(suppl 1):2–9.
48. Göthberg C, Bergendal T, Magnusson T. Complications after treatment with implant-supported fixed prostheses: A retrospective study. *Int J Prosthodont* 2003;16:201–207.
49. Engstrand P, Gröndahl K, Öhrnell LO, Nilsson P, Nannmark U, Brånemark P-I. Prospective follow up study of 95 patients with edentulous mandibles treated according to the Brånemark Novum concept. *Clin Oral Implants Res* 2003;5:3–10.
50. Bergkvist G, Sahlholm S, Nilner K, Lindh C. Implant-supported fixed prostheses in the edentulous maxilla. A 2-year clinical and radiological follow-up of treatment with non-submerged ITI implants. *Clin Oral Implants Res* 2004;15:351–359.



51. Romeo E, Lops D, Margutti E, Ghisolfi M, Chiapasco M, Vogel G. Long-term survival and success of oral implants in the treatment of full and partial arches: A 7-year prospective study with the ITI dental implant system. *Int J Oral Maxillofac Implants* 2004;19:247–259.
52. Preiskel HW, Tolka P. Cement- and screw-retained implant-supported prostheses: Up to 10 years of follow-up of a new design. *Int J Oral Maxillofac Implants* 2004;19:87–91.
53. Friberg B, Henningsson C, Jemt T. Rehabilitation of edentulous mandibles by means of turned Brånemark system implants after one-stage surgery: A 1-year retrospective study of 152 patients. *Clin Implant Dent Relat Res* 2005;7:1–9.
54. Hjalmarsson L, Smedberg JI. A 3-year retrospective study of Cresco frameworks: Preload and complications. *Clin Implant Dent Relat Res* 2005;7:189–199.
55. Maló P, Nobre Mde A, Petersson U, Wigren S. A pilot study of complete edentulous rehabilitation with immediate function using a new implant design: Case series. *Clin Implant Dent Relat Res* 2006;8:22–32.
56. Aparicio C, Ouazzani W, Garcia R, Arevalo X, Muela R, Fortes V. A prospective clinical study on titanium implants in the zygomatic arch for prosthetic rehabilitation of the atrophic edentulous maxilla with a follow-up of 6 months to 5 years. *Clin Implant Dent Relat Res* 2006;8:114–122.
57. De Bruyn H, Collaert B, Linden U, Johansson C, Albrektsson T. Clinical outcome of Screw Vent implants. A 7-year prospective follow-up study. *Clin Oral Implants Res* 1999;10:139–148.
58. Hellden L, Ericson G, Elliot A, et al. A prospective 5-year multicenter study of the Cresco implantology concept. *Int J Prosthodont* 2003;16:554–562.
59. Rasmusson L, Roos J, Bystedt H. A 10-year follow-up study of titanium dioxide-blasted implants. *Clin Implant Dent Relat Res* 2005;7:36–42.
60. Åstrand P, Engquist B, Dahlgren S, Grondahl K, Engquist E, Feldmann H. Astra Tech and Brånemark system implants: A 5-year prospective study of marginal bone reactions. *Clin Oral Implants Res* 2004;15:413–420.
61. Brånemark PI, Svensson B, van Steenberghe D. Ten-year survival rates of fixed prostheses on 4 or 6 implants ad modum Brånemark in full edentulism. *Clin Oral Implants Res* 1995;6:227–231.
62. Keller EE. Reconstruction of the severely atrophic edentulous mandible with endosseous implants: A 10-year longitudinal study. *J Oral Maxillofac Surg* 1995;53:305–320.
63. Schnitman PA, Wöhrle PS, Rubenstein JE, DaSilva JD, Wang NH. Ten-year results for Brånemark implants immediately loaded with fixed prostheses at implant placement. *Int J Oral Maxillofac Implants* 1997;12:495–503.
64. Eliasson A, Palmqvist S, Svensson B, Sondell K. Five-year results with fixed complete-arch mandibular prostheses supported by 4 implants. *Int J Oral Maxillofac Implants* 2000;15:505–510.
65. Wennerberg A, Carlsson GE, Jemt T. Influence of occlusal factors on treatment outcome: A study of 109 consecutive patients with mandibular implant-supported fixed prostheses opposing maxillary complete dentures. *Int J Prosthodont* 2001;14:550–555.
66. Peñarrocha M, Garcia B, Marti E, Boronat A. Rehabilitation of severely atrophic maxillae with fixed implant-supported prostheses using zygomatic implants placed using the sinus slot technique: Clinical report on a series of 21 patients. *Int J Oral Maxillofac Implants* 2007;22:645–650.
67. Brånemark PI, Engstrand P, Ohnell LO, et al. Brånemark Novum: A new treatment concept for rehabilitation of the edentulous mandible. Preliminary results from a prospective clinical follow-up study. *Clin Implant Dent Relat Res* 1999;1:2–16.
68. Collaert B, De Bruyn H. Early loading of four or five Astra Tech fixtures with a fixed cross-arch restoration in the mandible. *Clin Implant Dent Relat Res* 2002;4:133–135.
69. Peñarrocha M, Lárrazabal C, Balaguer J, Serrano C, Silvestre J, Bagán JV. Restoration with implants in patients with recessive dystrophic epidermolysis bullosa and patient satisfaction with the implant-supported superstructure. *Int J Oral Maxillofac Implants* 2007;22:651–655.
70. Tolman DE, Laney WR. Tissue-integrated dental prostheses: The first 78 months of experience at the Mayo Clinic. *Mayo Clin Proc* 1993;68:323–331.
71. Allen PF, McMillan AS, Smith DG. Complications and maintenance requirements of implant-supported prostheses provided in a UK dental hospital. *Br Dent J* 1997;182:298–302.
72. Balshi TJ, Ekfeldt A, Stenberg T, Vrielinck L. Three-year evaluation of Brånemark implants connected to angulated abutments. *Int J Oral Maxillofac Implants* 1997;12:52–58.
73. Shackleton JL, Solomons YF, Lownie MA. Experience with the Brånemark implant system: 1985–1995. *J Dent Assoc S Afr* 1996;51:810–814.
74. Misch CE, Wang HL. Immediate occlusal loading for fixed prostheses in implant dentistry. *Dent Today* 2003;22:50–56.
75. De Bruyn H, Collaert B, Linden U, Bjorn AL. Patient's opinion and treatment outcome of fixed rehabilitation on Brånemark implants. A 3-year follow-up study in private dental practices. *Clin Oral Implants Res* 1997;8:265–271.
76. Keller EE, Tolman DE, Eckert S. Surgical-prosthodontic reconstruction of advanced maxillary bone compromised with autogenous onlay block bone grafts and osseointegrated endosseous implants: A 12-year study of 32 consecutive patients. *Int J Oral Maxillofac Implants* 1999;14:197–209.
77. Friberg B, Grondahl K, Lekholm U, Brånemark PI. Long-term follow-up of severely atrophic edentulous mandibles reconstructed with short Brånemark implants. *Clin Implant Dent Relat Res* 2000;2:184–189.
78. Hedkvist L, Mattsson T, Hellden LB. Clinical performance of a method for the fabrication of implant-supported precisely fitting titanium frameworks: A retrospective 5- to 8-year clinical follow-up study. *Clin Implant Dent Relat Res* 2004;6:174–180.
79. Nelson K, Heberer S, Glatzer C. Survival analysis and clinical evaluation of implant-retained prostheses in oral cancer resection patients over a mean follow-up period of 10 years. *J Prosthet Dent* 2007;98:405–410.
80. Johansson G, Palmqvist S. Complications, supplementary treatment, and maintenance in edentulous arches with implant-supported fixed prostheses. *Int J Prosthodont* 1990;3:89–92.
81. Kallus T, Bessing C. Loose gold screws frequently occur in full-arch fixed prostheses supported by osseointegrated implants after 5 years. *Int J Oral Maxillofac Implants* 1994;9:169–178.
82. Henry PJ, Bower RC, Wall CD. Rehabilitation of the edentulous mandible with osseointegrated dental implants: 10 year follow-up. *Aust Dent J* 1995;40:1–9.
83. Watson RM, Davis DM. Follow up and maintenance of implant supported prostheses: A comparison of 20 complete mandibular overdentures and 20 complete mandibular fixed cantilever prostheses. *Br Dent J* 1996;181:321–327.
84. Friberg B, Nilson H, Olsson M, Palmqvist C. Mk II: The self-tapping Brånemark implant: 5-year results of a prospective 3-center study. *Clin Oral Implants Res* 1997;8:279–285.
85. Makkonen TA, Holmberg S, Niemi L, Olsson C, Tammisalo T, Peltola J. A 5-year prospective clinical study of Astra Tech dental implants supporting fixed bridges or overdentures in the edentulous mandible. *Clin Oral Implants Res* 1997;8:469–475.



86. Arvidson K, Bystedt H, Frykholm A, von Konow L, Lothigius E. Five-year prospective follow-up report of the Astra Tech Dental Implant System in the treatment of edentulous mandibles. *Clin Oral Implants Res* 1998;9:225–234.
87. Tinsley D, Watson CJ, Russell JL. A comparison of hydroxylapatite coated implant retained fixed and removable mandibular prostheses over 4 to 6 years. *Clin Oral Implants Res* 2001;12:159–166.
88. Jemt T, Bergendal B, Arvidson K, et al. Implant-supported welded titanium frameworks in the edentulous maxilla: A 5-year prospective multicenter study. *Int J Prosthodont* 2002;15:544–548.
89. Murphy WM, Absi EG, Gregory MC, Williams KR. A prospective 5-year study of two cast framework alloys for fixed implant-supported mandibular prostheses. *Int J Prosthodont* 2002;15:133–138.
90. Davis DM, Packer ME, Watson RM. Maintenance requirements of implant-supported fixed prostheses opposed by implant-supported fixed prostheses, natural teeth, or complete dentures: A 5-year retrospective study. *Int J Prosthodont* 2003;16:521–523.
91. Ekelund JA, Lindquist LW, Carlsson GE, Jemt T. Implant treatment in the edentulous mandible: A prospective study on Brånemark system implants over more than 20 years. *Int J Prosthodont* 2003;16:602–608.
92. Attard NJ, Zarb GA. Long-term treatment outcomes in edentulous patients with implant-fixed prostheses: The Toronto study. *Int J Prosthodont* 2004;17:417–424.
93. Engfors I, Örtorp A, Jemt T. Fixed implant-supported prostheses in elderly patients: A 5-year retrospective study of 133 edentulous patients older than 79 years. *Clin Implant Dent Relat Res* 2004;6:190–198.
94. Örtorp A, Jemt T. Clinical experiences of computer numeric control-milled titanium frameworks supported by implants in the edentulous mandible: A 5-year prospective study. *Clin Implant Dent Relat Res* 2004;6:199–209.
95. Jemt T, Johansson J. Implant treatment in the edentulous maxillae: A 15-year follow-up study on 76 consecutive patients provided with fixed prostheses. *Clin Implant Dent Relat Res* 2006;8:61–69.
96. Örtorp A, Jemt T. Clinical experiences with laser-welded titanium frameworks supported by implants in the edentulous mandible: A 10-year follow-up study. *Clin Implant Dent Relat Res* 2006;8:198–209.
97. Fischer K, Stenberg T, Hedin M, Sennerby L. Five-year results from a randomized, controlled trial on early and delayed loading of implants supporting full-arch prosthesis in the edentulous maxilla. *Clin Oral Implants Res* 2008;19:433–441.
98. Purcell BA, McGlumphy EA, Holloway JA, Beck FM. Prosthetic complications in mandibular metal-resin implant-fixed complete dental prostheses: A 5- to 9-year analysis. *Int J Oral Maxillofac Implants* 2008;23:847–857.
99. Örtorp A, Linden B, Jemt T. Clinical experiences with laser-welded titanium frameworks supported by implants in the edentulous mandible: A 5-year follow-up study. *Int J Prosthodont* 1999;12:65–72.
100. Jemt T. Fixed implant-supported prostheses in the edentulous maxilla. A five-year follow-up report. *Clin Oral Implants Res* 1994;5:142–147.
101. Jemt T, Lekholm U. Implant treatment in edentulous maxillae: A 5-year follow-up report on patients with different degrees of jaw resorption. *Int J Oral Maxillofac Implants* 1995;10:303–311.
102. Hemmings KW, Schmitt A, Zarb GA. Complications and maintenance requirements for fixed prostheses and overdentures in the edentulous mandible: A 5-year report. *Int J Oral Maxillofac Implants* 1994;9:191–196.
103. Lindquist LW, Carlsson GE, Glantz PO. Rehabilitation of the edentulous mandible with a tissue-integrated fixed prosthesis: A six-year longitudinal study. *Quintessence Int* 1987;18:89–96.
104. Lindquist LW, Carlsson GE, Jemt T. A prospective 15-year follow-up study of mandibular fixed prostheses supported by osseointegrated implants. Clinical results and marginal bone loss. *Clin Oral Implants Res* 1996;7:329–336.
105. Higgins JPT, Green S (eds). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.0.1 [updated September 2008]. The Cochrane Collaboration website. <http://www.cochrane-handbook.org>. Accessed 25 February 2011.
106. Needleman IG. A guide to systematic reviews. *J Clin Periodontol* 2002;29(suppl 3):6–9.
107. Hopewell S, Clarke M, Lefebvre C, Scherer R. Hand searching versus electronic searching to identify reports of randomized trials. *Cochrane Database Syst Rev* 2007;(2):MR000001.
108. Creugers NHJ, Kreulen CM, Snoek PA, de Kanter RJAM. A systematic review of single-tooth restorations supported by implants. *J Dent* 2000;28:209–217.
109. Egger M, Jüni P, Bartlett C, Holenstein F, Sterne J. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? *Empirical study. Health Technol Assess* 2003;7:1–76.
110. Goodacre CJ, Bernal G, Rungcharassaeng K, Kan JY. Clinical complications in fixed prosthodontics. *J Prosthet Dent* 2003;90:31–41.
111. Baran G, Boderick K, McCool J. Fatigue of restorative materials. *Crit Rev Oral Biol Med* 2001;12:350–360.
112. Oh W, Gotzen N, Anusavice KJ. Influence of corrector design on fracture probability of ceramic fixed-partial dentures. *J Dent Res* 2002;81:623–627.
113. Bell AM, Kurzeja R, Gamberg MG. Ceramometal crowns and bridges. Focus on failures. *Dent Clin North Am* 1985;29:763–778.
114. Riley EJ. Ceramo-metal restoration. State of the science. *Dent Clin North Am* 1977;21:669–682.
115. Sahin S, Cehreli MC, Yalcin E. The influence of functional forces on the biomechanics of implant-supported prostheses: A review. *J Dent* 2002;30:271–282.
116. Duyck J, Van Oosterwyck H, Vander Sloten J, De Cooman M, Puers R, Naert I. Magnitude and distribution of occlusal forces on oral implants supporting fixed prostheses: An in vivo study. *Clin Oral Implants Res* 2000;11:465–475.
117. Simon RL. Single implant-supported molar and premolar crowns: A ten-year retrospective clinical report. *J Prosthet Dent* 2003;90:517–521.
118. Weinberg L. The biomechanics of force distribution in implant-supported prostheses. *Int J Oral Maxillofac Implants* 1993;8:19–31.
119. McGlumphy E. Keeping implant screws tight: The solution. *J Dent Symp* 1993;1:20–23.
120. Stewart RB, Desjardins RP, Laney WR, Chao EY. Fatigue strength of cantilevered metal frameworks for tissue-integrated prostheses. *J Prosthet Dent* 1992;68:83–92.
121. Craig RG (ed). *Restorative Dental Materials*, ed 8. St Louis: Mosby, 1989.
122. O'Brien WJ (ed). *Dental Materials: Properties and Selection*. Chicago: Quintessence, 1977.
123. Phillips RW. Restorative resins. In: Phillips RW, Skinner EW (ed). *Skinner's Science of Dental Materials*, ed 9. Philadelphia: Saunders, 1991:215–248.
124. Eckert SE, Choi YG, Koka S. Methods for comparing the results of different studies. *Int J Oral Maxillofac Implants* 2003;18:697–705.
125. Attard NJ, Zarb GA, Laporte A. Long-term treatment costs associated with implant-supported mandibular prostheses in edentulous patients. *Int J Prosthodont* 2005;18:117–123.